natgillin/translations-raw huggingface dataset:
The data showed that antibody levels at day 42 after vaccination for each group remained at levels similar to day 21 after vaccination and above levels from the laboratory studies.
Podatki so pokazali, da so ravni protiteles na 42. dan po cepljenju za vse skupine ostale podobne ravnem, doseženim na 21. dan po cepljenju, in nad ravnmi iz laboratorijskih študij.
The data showed that antibody levels at day 63 after vaccination for each group remained at levels similar to day 35 after vaccination and above levels from the laboratory studies.
Podatki so pokazali, da so ravni protiteles na 63. dan po cepljenju za vse skupine ostale podobne ravnem, doseženim na 35. dan po cepljenju, in nad ravnmi iz laboratorijskih študij.
Laboratory studies showed that in sheep the vaccine starts to be effective 39 days after vaccination and protection lasts for 1 year.
Laboratorijske študije so pokazale, da cepivo pri ovcah začne učinkovati 39 dni po cepljenju, zaščita pa traja eno leto.
Revaccination with one injection is required after 1 year.
Po enem letu je treba cepljenje ponoviti z enim odmerkom.
How is Syvazul BTV used?
Kako se zdravilo Syvazul BTV uporablja?
The vaccine starts to be effective 21 days after completion of the initial vaccination course and protection lasts one year.
Cepivo začne učinkovati 21 dni po zaključku začetnega sklopa cepljenja, zaščita pa traja eno leto.
In a field study, 3 groups of 35 lambs from 3 months of age (with no antibodies to bluetongue virus) received vaccination with vaccines containing BTV-1, BTV-8 and BTV 1+8.
V terenski študiji so tri skupine po 35 jagnjet v starosti od treh mesecev dalje (brez protiteles proti virusu modrikastega jezika) bile cepljene s cepivi, ki so vsebovala serotip 1 ali 8 oziroma kombinacijo serotipov 1 in 8 virusa modrikastega jezika.
Laboratory studies showed that in cattle the vaccine starts to be effective 21 days after completion of the initial vaccination course and protection lasts one year.
Laboratorijske študije so pokazale, da cepivo pri govedu začne učinkovati 21 dni po zaključku začetnega sklopa cepljenja, zaščita pa traja eno leto.
How does Syvazul BTV work?
Kako zdravilo Syvazul BTV deluje?
The vaccine is given as a single injection under the skin to sheep from 3 months of age.
Cepivo se ovcam od starosti treh mesecev injicira v podkožje v enem odmerku.
The vaccine starts to be effective 39 days after vaccination and protection lasts for 1 year.
Cepivo začne učinkovati 39 dni po cepljenju, zaščita pa traja eno leto.
Groups of 25 calves from 2 months of age (with no antibodies to bluetongue virus) were vaccinated with vaccines containing BTV-1, BTV-8 and BTV 1+8 in a field study.
V terenski študiji so bile skupine po 25 teličkov v starosti od dveh mesecev dalje (brez protiteles proti bolezni modrikastega jezika) cepljenje s cepivi, ki so vsebovala serotip 1 ali 8 oziroma kombinacijo serotipov 1 in 8 virusa modrikastega jezika.
Do not take it if you are not going to eat a main meal.
Ne vzemite ga, če ne nameravate pojesti glavnega obroka.
The clinical experience in patients over 75 years of age is limited.
Klinične izkušnje pri bolnikih, starejših od 75 let, so omejene.
Your treatment may need to be adjusted.
Mogoče bo treba prilagoditi vaše zdravljenje.
Post-marketing data revealed very rare cases of erythema multiforme.
Postmarketinški podatki so razkrili zelo redke primere multiformnega eritema.
Approximately
Približno
Your doctor may adjust the dose of these medicines.
Zdravnik vam lahko prilagodi odmerek teh zdravil.
Absolute oral bioavailability is estimated to be 72%.
Ocenjujejo, da je absolutna peroralna biološka uporabnost 72 %.
Swallow the tablets whole with a glass of water before the meal.
Tablete pogoltnite cele s kozarcem vode pred obrokom.
Talk to your doctor if you have any further questions or you think that any of these may apply to you.
Pogovorite se z zdravnikom, če imate še kakšna vprašanja ali če mislite, da utegne kaj od zgoraj navedenega veljati za vas.
• Pregnancy and breast-feeding (see section 4.6)
• z nosečnostjo in dojenjem (glejte poglavje 4.6);
Nateglinide should be taken within 1 to 30 minutes before meals (usually breakfast, lunch and dinner).
Nateglinid je treba jemati 1 do 30 minut pred obroki (navadno pred zajtrkom, kosilom in večerjo).
Studies in animals have shown developmental toxicity (see section 5.3).
Študije na živalih so pokazale vpliv na razvoj (glejte poglavje 5.3).
Frequencies are defined as: common (>1/100, <1/10); uncommon (>1/1,000, <1/100); rare (>1/10,000, <1/1,000); very rare (<1/10,000).
Pogostnost je definirana takole: pogosti (>1/100, <1/10); občasni (>1/1.000, <1/100); redki (>1/10.000, <1/1.000); zelo redki (<1/10.000).
In some cases your doctor may prescribe higher doses.
V nekaterih primerih vam bo zdravnik predpisal višje odmerke.
6-16% of the administered dose was excreted in the urine as unchanged drug.
6-16 % danega odmerka se je izločilo v urinu v obliki nespremenjenega zdravila.
These were generally mild in nature and easily handled by intake of carbohydrates when necessary.
V splošnem so bili blage narave in zlahka obvladljivi z zaužitjem ogljikovih hidratov, kadar je bilo potrebno.
It is used by people with type 2 diabetes.
Uporabljajo ga ljudje s sladkorno boleznijo tipa 2.
If any of these apply to you, monitor your blood sugar levels more carefully.
Če kaj od zgoraj navedenega velja za vas, skrbneje spremljajte svojo raven krvnega sladkorja.
There is no experience in pregnant women, therefore the safety of Trazec in pregnant women cannot be assessed.
Ni izkušenj o uporabi pri nosečnicah, zato varnost uporabe Trazeca pri nosečnicah ne more biti ocenjena.
Trazec is not recommended for children and adolescents (under 18 years of age) because its effects in this age group have not been studied.
Trazec ni priporočljiv za otroke in mladostnike (mlajše od 18 let), ker njegovih učinkov v tej starostni skupini niso proučevali.
If you forget to take a tablet simply take the next one before your next meal.
Če pozabite vzeti tableto, preprosto vzemite naslednjo tableto pred naslednjim obrokom.
• Diabetic ketoacidosis, with or without coma
• z diabetično ketoacidozo, s komo ali brez nje;
At such times, it may be necessary to discontinue oral hypoglycaemic treatment and replace it with insulin on a temporary basis.
Takrat utegne biti potrebno prekiniti peroralno hipoglikemično zdravljenje in ga začasno nadomestiti z insulinom.
DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION Date of first authorisation: 03.04.2001
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 03.04.2001
Treatment is therefore not recommended in these patient groups.
Pri teh skupinah bolnikov zdravljenje zato ni priporočljivo.
If you feel as if you are about to have a severe hypoglycaemic attack (which may lead to loss of consciousness or seizure), call for urgent medical help - or make sure that someone else does this for you.
Če imate občutek, da boste dobili hud napad hipoglikemije (ki lahko povzroči izgubo zavesti ali napad krčev), pokličite nujno medicinsko pomoč - ali poskrbite, da to namesto vas stori kdo drug.
Alcohol may upset the control of your blood sugar so you are advised to talk to your doctor about drinking alcohol while taking Trazec.
Alkohol lahko poslabša kontrolo vašega krvnega sladkorja, zato je priporočljivo, da se glede uživanja alkohola v času jemanja Trazeca pogovorite z zdravnikom.
Insulin is a substance produced by a body organ called the pancreas.
Insulin je snov, ki ga izdeluje telesni organ, ki se imenuje trebušna slinavka.
This depolarises the beta cell and leads to an opening of the calcium channels.
To depolarizira celico beta in povzroči odpiranje kalcijevih kanalčkov.
It helps to decrease blood sugar levels, especially after meals.
Pomaga zniževati koncentracijo krvnega sladkorja, zlasti po obrokih hrane.
If you have any further questions, ask your doctor or pharmacist.
- Če imate dodatna vprašanja, se posvetujte z zdravnikom ali s farmacevtom.
Even though you are taking medicines for your diabetes, it is important to keep following the diet and/or exercise your doctor has recommended for you.
Čeprav kot sladkorni bolnik jemljete zdravila, je pomembno, da se še naprej držite diete in/ali programa telesne aktivnosti, ki vam ju je priporočil zdravnik.
Take special care to avoid low blood sugar.
Zlasti poskrbite, da se izognete nizkemu krvnemu sladkorju.
Your doctor will prescribe Trazec together with another oral anti-diabetic containing metformin.
Zdravnik vam bo predpisal Trazec skupaj z drugim peroralnim antidiabetikom, ki vsebuje metformin.
Some people are more likely to get symptoms of low blood sugar than others.
Pri nekaterih ljudeh se bodo verjetneje pojavili simptomi nizkega krvnega sladkorja kot pri drugih.
It is best to take it right before a main meal but you can take it up to 30 minutes before.
Najbolje je, če ga vzamete tik pred glavnim obrokom, lahko pa ga vzamete tudi do 30 minut pred obrokom.
They can also be caused by lack of food or too high a dose of any anti-diabetic medicine you are taking.
Neželene učinke lahko povzroči tudi pomanjkanje hrane ali prevelik odmerek kakega zdravila za sladkorno bolezen, ki ga jemljete.
(This kind of diabetes is also called non-insulin-dependent
(Ta vrsta sladkorne bolezni se imenuje tudi insulinsko neodvisni diabetes mellitus.)
The amount of Trazec that you need may change if you take other medicines as these may cause your blood sugar levels to go up or down.
Vaše potrebe po Trazecu se lahko spremenijo, če jemljete druga zdravila, ker to lahko povzroči zvišanje ali znižanje vaših vrednosti krvnega sladkorja.
Take Trazec before meals (see section 3, “How to take Trazec”).
Jemljite Trazec pred obroki (glejte poglavje 3, “Kako jemati zdravilo Trazec”).
Although it is not known whether nateglinide is excreted in human milk, the potential for hypoglycaemia in breast-fed infants may exist and therefore nateglinide should not be used in lactating women.
Čeprav ni znano, ali se nateglinid izloča v materino mleko pri ljudeh, lahko pri dojenih dojenčkih obstaja potencial za hipoglikemijo, zato se nateglinid pri doječih materah ne sme uporabljati.
Most of the [14C] nateglinide is excreted in the urine (83%), with an additional 10% eliminated in the faeces.
Večina nateglinida, označenega s [14C], se izloči v urinu (83 %), dodatnih 10 % pa se ga odstrani iz telesa z blatom.
It is recommended that Trazec be administered prior to meals.
Priporočljivo je jemanje Trazeca pred obroki.
This may be increased to 120 mg three times daily.
Odmerek se sme povečati na 120 mg trikrat na dan.
Approximately 75% of the administered [14C] nateglinide is recovered in the urine within six hours post-dose.
Približno 75 % danega [14C] nateglinida v šestih urah po odmerku prestrežemo v urinu.
Trazec and children and adolescents
Trazec ter otroci in mladostniki
Nateglinide was not teratogenic in rats.
Pri podganah nateglinid ni bil teratogen.
If you forget to take Trazec
Če ste pozabili vzeti zdravilo Trazec
There are no data available on the use of nateglinide in patients under 18 years of age, and therefore its use in this age group is not recommended.
O uporabi nateglinida pri bolnikih, mlajših od 18 let, ni podatkov, zato njegova uporaba v tej starostni skupini ni priporočljiva.
Nateglinide should not be used in monotherapy.
Splošno Nateglinid se ne sme uporabljati v monoterapiji.
Important information about some of the ingredients of Trazec Trazec tablets contain lactose monohydrate.
Pomembne informacije o nekaterih sestavinah zdravila Trazec Tablete Trazec vsebujejo laktozo monohidrat.
As patients with severe liver disease were not studied, nateglinide is contraindicated in this group.
Ker bolniki s hudo boleznijo jeter niso proučeni, je nateglinid v tej skupini kontraindiciran.
Electrophysiological studies demonstrate that nateglinide has 45-300-fold selectivity for pancreatic beta cell versus cardiovascular K+ATP channels.
Elektrofiziološke študije kažejo, da ima nateglinid 45-300-kratno selektivnost za pankreatično celico beta v primerjavi s kardiovaskularnimi kanalčki K+ATP.
However, there is a delay in the rate of absorption characterised by a decrease in Cmax and a delay in time to peak plasma concentration (tmax).
Vendar se absorpcija upočasni, za kar je značilno zmanjšanje Cmax in podaljšan čas do najvišje koncentracije v plazmi (tmax).
Hypoglycaemia has been observed in patients with type 2 diabetes on diet and exercise, and in those treated with oral antidiabetic agents (see section 4.8).
Hipoglikemija je bila opazovana pri bolnikih s sladkorno boleznijo tipa 2 na dieti in pri telesnem naporu ter pri tistih, ki se zdravijo s peroralnimi antidiabetiki (glejte poglavje 4.8).
Interaction studies with a 3A4 inhibitor have not been carried out in vivo.
Študije medsebojnega delovanja z zaviralcem 3A4 in vivo niso opravljene.
An outcome study has not been conducted with nateglinide, therefore the long-term benefits associated with improved glycaemic control have not been demonstrated.
Z nateglinidom ni bila opravljenja študija izida, zato niso dokazane dolgoročne koristi, povezane z izboljšanim uravnavanjem koncentracije glukoze v krvi.
Do not take a double dose of Trazec to make up for the one that you missed.
Ne vzemite dvojnega odmerka Trazeca, da bi nadomestili izpuščenega.
• Type 1 diabetes (insulin-dependent diabetes mellitus, C-peptide negative)
• s sladkorno boleznijo tipa 1 (od insulina odvisna, na C-peptid negativna sladkorna bolezen);
Trazec tablets start to act quickly after you take them and are eliminated from the body rapidly.
Tablete Trazeca začnejo delovati kratek čas po zaužitju in se hitro izločijo iz telesa.
The recommended starting dose is 60 mg three times daily before meals, particularly in patients who are near goal HbA1c.
Priporočeni začetni odmerek je 60 mg trikrat na dan pred obroki, posebno pri bolnikih, pri katerih je glikozilirani hemoglobin (HbA1c) blizu ciljnemu.
Always take Trazec exactly as your doctor has told you.
Jemljite Trazec, kot vam je naročil zdravnik.
However, an overdose may result in an exaggerated glucose-lowering effect, with the development of hypoglycaemic symptoms.
Lahko pa prevelik odmerek povzroči pretiran hipoglikemični učinek z razvojem hipoglikemičnih simptomov.
In a clinical study in patients, Trazec was administered in increasing doses up to 720 mg a day for 7 days and was well tolerated.
V klinični študiji so bolniki prejeli Trazec v naraščajočih odmerkih do 720 mg na dan 7 dni dolgo in so ga bolniki dobro prenašali.
Dose adjustments should be based on periodic glycosylated haemoglobin (HbA1c) measurements.
Prilagoditve odmerjanja morajo temeljiti na periodičnih meritvah glikoziliranega hemoglobina (HbA1c).
For any information about this medicinal product, please contact the local representative of the
Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom:
In type 2 diabetic patients, the insulinotropic response to a meal occurs within the first 15 minutes following an oral dose of nateglinide.
Pri bolnikih s sladkorno boleznijo tipa 2 se insulinotropni odgovor na obrok pojavi v prvih 15 minutah po peroralnem odmerku nateglinida.
Its effect is dependent on functioning beta cells in the pancreas islets.
Njegov učinek je odvisen od delujočih celic beta v otočkih trebušne slinavke.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev, se pred jemanjem tega zdravila posvetujte s svojim zdravnikom.
In patients with type 2 diabetes, the body may not start producing insulin quickly enough after meals.
Pri bolnikih s sladkorno boleznijo tipa 2 telo po zaužitju hrane ne začne izdelovati insulina dovolj hitro.
Do not breast-feed during treatment with Trazec.
Med zdravljenjem s Trazecom ne dojite.
When given post-prandially, the extent of nateglinide absorption (AUC) remains unaffected.
Jemanje nateglinida po obroku ne vpliva na obseg njegove absorpcije (AUC).
Medicines, including Trazec, may also produce symptoms of low blood sugar.
Zdravila, med drugim Trazec, utegnejo tudi povzročiti simptome nizkega krvnega sladkorja.
Plasma concentrations decline rapidly and the elimination half-life of nateglinide typically averaged 1.5 hours in all studies of Trazec in volunteers and type 2 diabetic patients.
Plazemske koncentracije se hitro zmanjšujejo in razpolovni čas odstranjevanja nateglinida iz telesa je bil povprečno 1,5 ure, kar je bilo značilno za vse študije Trazeca pri prostovoljcih in bolnikih s sladkorno boleznijo tipa 2.
The efficacy of nateglinide in combination with metformin has been compared to the combination of gliclazide plus metformin in a 6-month randomised, double-blind trial in 262 patients using a superiority design.
Učinkovitost nateglinida v kombinaciji z metforminom so primerjali s kombinacijo gliklazida plus metformina v 6-mesečnem randomiziranem, dvojno slepem preskusu pri 262 bolnikih z uporabo zasnove z namenom dokazovanja večje primernosti zdravila.
In vitro studies show that nateglinide is extensively bound (97-99%) to serum proteins, mainly serum albumin and to a lesser extent alpha1-acid glycoprotein.
Raziskave in vitro kažejo, da se nateglinid v zelo veliki meri (97-99 %) veže na serumske beljakovine, predvsem na serumske albumine in v manjši meri na α1-kisli glikoprotein.
Blisters: PVC/PE/PVDC moulded foil with aluminium lidding foil.
Pretisni omoti: odtisnjena folija iz PVC/PE/PVDC z aluminijasto prekrivno folijo.
Symptoms of hypoglycaemia (unconfirmed by blood glucose levels) were observed in patients whose baseline HbA1c was close to the therapeutic target (HbA1c <7.5%).
Simptomi hipoglikemije (ki ni bila potrjena s koncentracijami glukoze v krvi) so bili opazovani pri bolnikih, katerih izhodiščni HbA1c je bil blizu terapevtske tarče (HbA1c < 7,5 %).
Severe hypoglycaemic reactions with coma, seizure or other neurological symptoms should be treated with intravenous glucose.
Težke hipoglikemične reakcije s komo, napadi krčev ali drugimi nevrološkimi simptomi je treba zdraviti z intravensko glukozo.
Packs contain 12, 60, 84, 120 and 360 tablets.
Škatle vsebujejo po 12, 60, 84, 120 in 360 tablet.
The risk of hypoglycaemia in type 2 diabetic patients may be increased by strenuous physical exercise, or ingestion of alcohol.
Nevarnost hipoglikemije pri bolnikih s sladkorno boleznijo tipa 2 lahko poveča hud telesni napor ali uživanje alkohola.
The usual dose of Trazec to start with is 60 mg before the three main meals.
Običajni začetni odmerek Trazeca je 60 mg pred tremi glavnimi obroki.
When a patient stabilised on any oral hypoglycaemic agent is exposed to stress such as fever, trauma, infection or surgery, a loss of glycaemic control may occur.
Kadar je bolnik, ki je stabiliziran na kateremkoli peroralnem hipoglikemičnem sredstvu, izpostavljen stresu, na primer zvišani telesni temperaturi, poškodbi, okužbi ali operaciji, lahko pride do izgube kontrole nad glikemijo.
In debilitated or malnourished patients the initial and maintenance dosage should be conservative and careful titration is required to avoid hypoglycaemic reactions.
Pri oslabljenih ali podhranjenih bolnikih morata biti začetno in vzdrževalno odmerjanje konzervativna in potrebno je skrbno prilagajanje odmerjanja terapevtskemu učinku, da se preprečijo hipoglikemične reakcije.
Take Trazec daily until your doctor tells you to stop.
Kako dolgo jemati zdravilo Trazec Jemljite Trazec vsak dan, dokler vam zdravnik ne naroči, da ga prenehajte jemati.
SPECIAL STORAGE CONDITIONS Do not store above 30°C.
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte pri temperaturi do 30 °C.
Elderly, malnourished patients and those with adrenal or pituitary insufficiency or severe renal impairment are more susceptible to the glucoselowering effect of these treatments.
Starejši bolniki, podhranjeni bolniki in tisti z insuficienco nadledvičnic ali hipofize ali hudo ledvično okvaro so dovzetnejši za hipoglikemični učinek teh vrst zdravljenja.
The dosage of nateglinide should be determined by the physician according to the patient's
Odmerjanje nateglinida mora določiti zdravnik v skladu z bolnikovimi potrebami.
Trazec, like other oral antidiabetic agents, is not recommended for use in pregnancy.
Trazec, podobno kot drugi peroralni antidiabetiki, v nosečnosti ni priporočljiv.
when taken before a meal, restores early or first phase insulin secretion, which is lost in patients with type 2 diabetes, resulting in a reduction in post-meal glucose and HbA1c.
Če nateglinid vzamemo pred obrokom, spet vzpostavi zgodnjo sekrecijo oziroma prvo fazo sekrecije insulina, ki jo bolniki s sladkorno boleznijo tipa 2 izgubijo, kar ima za posledico znižanje postprandialne glukoze in HbA1c.
Each blister pack contains 12, 60, 84, 120 or 360 tablets.
Vsako pakiranje pretisnih omotov vsebuje 12, 60, 84, 120 ali 360 tablet.
In type 2 diabetic patients given Trazec over the dose range 60 to 240 mg before three meals per day for one week, nateglinide showed linear pharmacokinetics for both AUC and Cmax, and
Pri bolnikih s sladkorno boleznijo tipa 2, ki so dobivali Trazec v mejah odmerkov od 60 do 240 mg pred tremi obroki na dan en teden dolgo, je nateglinid kazal linearno farmakokinetiko tako za AUC kot za Cmax, tmax pa je bil od odmerka neodvisen.
Conversely, these medicinal products had no effect on the pharmacokinetics of nateglinide.
Obratno ta zdravila niso vplivala na farmakokinetiko nateglinida.
It is usually taken immediately (1 minute) before a meal but may be taken up to 30 minutes before meals.
Navadno ga bolniki jemljejo tik (1 minuto) pred obrokom, lahko pa tudi do 30 minut pred obroki.
Nateglinide is rapidly and almost completely (≥ 90%) absorbed from an oral solution.
Iz peroralne raztopine se nateglinid absorbira hitro in skoraj popolnoma (≥ 90 %).
Nateglinide efficacy was inferior to that of metformin in monotherapy (decrease in HbA1c (%) with metformin 500 mg three times daily monotherapy: -1.23 [95% CI: -1.48; -0.99] and with nateglinide 120 mg three times daily monotherapy -0.90 [95% CI: -1.14; -0.66]).
Učinkovitost nateglinida je bila slabša od učinkovitosti metformina v okviru monoterapije (znižanje HbA1c (%) pri monoterapiji z metforminom 500 mg trikrat na dan: -1,23 [95 %-ni interval zaupanja:1,48; -0,99] in pri monoterapiji z nateglinidom 120 mg trikrat na dan -0,90 [95 %-ni interval zaupanja: -1,14; -0,66]).
Hypoglycaemic symptoms without loss of consciousness or neurological findings should be treated with oral glucose and adjustments in dosage and/or meal patterns.
Hipoglikemične simptome brez izgube zavesti ali nevroloških znakov je treba zdraviti s peroralno glukozo in prilagajanjem odmerjanja in/ali vzorcev obrokov.
In an interaction trial with sulfinpyrazone, a CYP2C9 inhibitor, a modest increase in nateglinide AUC (~28%) was observed in healthy volunteers, with no changes in the mean Cmax and elimination half-life.
V preskušanju interakcij z inhibitorjem CYP2C9 sulfinpirazonom je bil pri zdravih prostovoljcih opažen zmeren porast AUC nateglinida (~28 %), brez sprememb srednje Cmax in razpolovnega časa izločanja iz telesa.
Nateglinide and its metabolites are rapidly and completely eliminated.
Nateglinid in njegovi presnovki se hitro in popolnoma izločijo iz telesa.
Trazec is contraindicated in patients with:
Trazec je kontraindiciran pri bolnikih:
Like all medicines, Trazec can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Trazec neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
• Hypersensitivity to the active substance or to any of the excipients
• s preobčutljivostjo za zdravilno učinkovino ali katerokoli pomožno snov;
Ask your doctor or pharmacist for advice before taking any medicine while you are pregnant or breast
Posvetujte se z zdravnikom ali s farmacevtom, preden v nosečnosti ali med dojenjem vzamete katerokoli zdravilo.
These symptoms included sweating, trembling, dizziness, increased appetite, palpitations, nausea, fatigue, and weakness.
Ti simptomi so zajemali znojenje, tresenje, vrtoglavost, povečan tek, palpitacije, navzejo, utrujenost in oslabelost.